Skip to main content

Clinical development of a VAR2CSA-based placental malaria vaccine

Obiettivo

Placental malaria, a special form of malaria targeting pregnant women, causes the death of 200,000 infants and 10,000 pregnant women each year. Placental malaria has no sustainable cure. The overall success criterion of the proposed project is to enable the manufacture of a vaccine, which protects fetus and mother against the adverse effects of malaria during pregnancy. Administered to women before they get pregnant the vaccine should induce antibodies that prevent the binding of malaria parasites in the placenta. Vaccine development is facilitated by the availability of an in vitro assay that predicts clinical immunity. With this proposal, we seek funding to produce the first placental malaria vaccine and perform the first clinical studies in humans. In parallel, we will prepare a field site and a protocol for a phase II study in African women. The partners behind the application have secured funding for ongoing work to down-select the current VAR2CSA lead antigens and to produce GLP batch protein for toxicology studies in animals, prior to the initiation of the work proposed here. Under the proposed FP7 project an SME, ExpreS2ion Biotechnologies will optimize production and purification of the vaccine. ExpreS2ion Biotechnologies operates a unique expression platform and this project will enable the company to expand their business into downstream process development. The academic partners are strong. Researchers at University of Copenhagen, (UCPH) originally discovered the vaccine protein and they have been collaborating with Institut de Recherche pour le Developpement (IRD) and Université d'Abomey-Calavi (UAC) to optimize vaccine antigens and to prepare sites for clinical testing. The European Vaccine Initiative (EVI) will provide product management and coordinate execution of the phase I clinical trial. Thus, this study will provide a product to continue into efficacy studies in Africa, which could be initiated shortly after the end of the project.

Invito a presentare proposte

FP7-HEALTH-2012-INNOVATION-1
Vedi altri progetti per questo bando

Coordinatore

KOBENHAVNS UNIVERSITET
Indirizzo
Norregade 10
1165 Kobenhavn
Danimarca

Mostra sulla mappa

Tipo di attività
Higher or Secondary Education Establishments
Contatto amministrativo
Tine Mathiesen (Ms.)
Contributo UE
€ 2 096 620

Partecipanti (5)

EXPRES2ION BIOTECHNOLOGIES APS
Danimarca
Contributo UE
€ 996 648
Indirizzo
Agern Alle 1
2970 Horsholm

Mostra sulla mappa

Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Willem Adriaan De Jongh (Dr.)
INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT
Francia
Contributo UE
€ 488 960
Indirizzo
Boulevard De Dunkerque 44 Cs 90009
13572 Marseille

Mostra sulla mappa

Tipo di attività
Research Organisations
Contatto amministrativo
Jean Albergel (Mr.)
EUROPEAN VACCINE INITIATIVE EWIV
Germania
Contributo UE
€ 435 296,58
Indirizzo
Vossstrasse 2 Geb 4040
69115 Heidelberg

Mostra sulla mappa

Tipo di attività
Research Organisations
Contatto amministrativo
Sten Larsen (Mr.)
UNIVERSITE D'ABOMEY-CALAVI
Benin
Contributo UE
€ 904 056
Indirizzo
Campus Universitaires D Abomey
01 Abomey Calavi

Mostra sulla mappa

Tipo di attività
Higher or Secondary Education Establishments
Contatto amministrativo
Cynel Kahoun (Mr.)
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Germania
Contributo UE
€ 1 013 400
Indirizzo
Geschwister-scholl-platz
72074 Tuebingen

Mostra sulla mappa

Tipo di attività
Higher or Secondary Education Establishments
Contatto amministrativo
Stefanie Bolte (Dr.)